Modality
ERT
MOA
MALT1i
Target
CD47
Pathway
Sphingolipid
GA
Development Pipeline
Preclinical
~Jul 2011
→ ~Oct 2012
Phase 1
~Jan 2013
→ ~Apr 2014
Phase 2
~Jul 2014
→ ~Oct 2015
Phase 3
~Jan 2016
→ ~Apr 2017
NDA/BLA
Jul 2017
→ Jul 2027
NDA/BLACurrent
NCT06098725
680 pts·GA
2017-07→2027-07·Active
NCT03460113
141 pts·GA
2017-11→TBD·Recruiting
821 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-071.3y awayPh3 Readout· GA
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
NDA/BLA
Active
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-07-07 · 1.3y away
GA
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06098725 | NDA/BLA | GA | Active | 680 | PASI75 |
| NCT03460113 | NDA/BLA | GA | Recruiting | 141 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 |